11/20
08:13 am
cgon
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting [Yahoo! Finance]
Low
Report
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting [Yahoo! Finance]
11/20
08:00 am
cgon
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Low
Report
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
11/14
07:09 am
cgon
CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
11/12
08:33 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
High
Report
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
11/12
08:00 am
cgon
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
Medium
Report
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/11
08:00 am
cgon
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
Low
Report
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
10/24
07:16 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $60.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $60.00 price target on the stock.
10/8
11:48 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $65.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $65.00 price target on the stock.
10/1
07:16 am
cgon
We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth [Yahoo! Finance]
Medium
Report
We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth [Yahoo! Finance]
9/23
07:59 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $66.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $66.00 price target on the stock.
9/17
08:02 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
9/16
12:55 pm
cgon
CG Oncology surges 7%; seen benefitting from J&J bladder cancer asset data [Seeking Alpha]
Low
Report
CG Oncology surges 7%; seen benefitting from J&J bladder cancer asset data [Seeking Alpha]
8/30
08:00 am
cgon
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Low
Report
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
8/29
07:31 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
8/28
04:35 pm
cgon
Roth starts CG Oncology at buy, cites anticipated FDA filing [Seeking Alpha]
Low
Report
Roth starts CG Oncology at buy, cites anticipated FDA filing [Seeking Alpha]
8/27
06:30 pm
cgon
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $65.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $65.00 price target on the stock.